THE SCIENCE BEHIND HAIRGENETIX

Hairgenetix products are based on three independently researched mechanisms: copper peptides (GHK-Cu and AHK-Cu), scalp microneedling, and PDRN. The copper peptide evidence includes a 2012 review by Pickart et al. (PubMed 23960389) demonstrating up to 40% increase in follicle size. The microneedling evidence is anchored by Dhurat et al.’s 2013 RCT showing 82% patient response rate. PDRN efficacy is supported by a 2024 clinical study (PubMed 38842633). In our own 150-day trial with 30 participants, 93% reduction in hair shedding was achieved.

Clinical studies show measurable improvements in hair density and thickness after 12–16 weeks of consistent treatment. Early signs — such as reduced shedding and increased scalp vitality — may appear within 4–6 weeks. In our 150-day clinical trial, 75% of participants saw visible improvement by day 90. Long-term use (6+ months) is associated with continued improvement in hair density.

Yes — this is the core principle behind Hairgenetix products. The three mechanisms work through different biological pathways: copper peptides activate Wnt/β-catenin signalling, microneedling triggers wound-healing growth factors, and PDRN promotes tissue repair via the A2A receptor. Combining them creates a synergistic effect that addresses multiple causes of hair thinning simultaneously. The Hairgenetix serum is formulated with all three active compounds for combined delivery.

Copper peptides (GHK-Cu and AHK-Cu) are naturally occurring compounds in the human body with no significant systemic side effects reported in published studies. Minoxidil, while extensively studied, can cause scalp irritation, unwanted facial hair growth, and in rare cases cardiovascular effects. Unlike minoxidil, copper peptides do not require continuous indefinite use to maintain results — though ongoing maintenance is recommended. Consult your healthcare provider before switching treatments.

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide found in human plasma, saliva, and urine. It has the broadest evidence base, with studies showing effects on wound healing, collagen synthesis, and hair follicle enlargement. AHK-Cu (alanyl-histidyl-lysine copper) is a synthetic analogue specifically optimised for hair follicle stimulation — studies show it promotes dermal papilla cell proliferation and inhibits follicle cell apoptosis. Hairgenetix uses both peptides for maximum efficacy.

At-home microneedling devices with 0.5–1.5mm needle depth can replicate many of the benefits of clinic mesotherapy sessions. The key factors are needle depth, serum quality, and treatment consistency. The Hairgenetix mesotherapy pen uses 24-karat gold micro-needles with adjustable depth, delivering clinical-grade copper peptide serum directly to the scalp. While deep-injection clinic mesotherapy (2–4mm) targets deeper tissue layers, at-home protocols have shown comparable results for hair growth in multiple studies at a fraction of the cost.

Our clinical trial included participants with androgenetic alopecia (pattern baldness), telogen effluvium (stress-related shedding), and diffuse thinning. Results were positive across all non-scarring hair loss types. The copper peptide and microneedling mechanisms target the hair follicle growth cycle directly, making them effective for most common forms of hair thinning. However, mesotherapy cannot regrow hair where follicles are permanently destroyed (cicatricial/scarring alopecia).

All studies cited on this page are available on PubMed, the U.S. National Library of Medicine’s database of peer-reviewed biomedical literature. Key studies include: Pickart et al. 2012 (PubMed 23960389), Dhurat et al. 2013 (PMC3746236), and PDRN efficacy 2024 (PubMed 38842633). For a complete list of all referenced studies, see the Citations section below or visit our dedicated research pages for copper peptides, microneedling, and PDRN.